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A B S T R A C T
Historically, higher levels of serum testosterone were presumed deleterious to the cardiovascular
system. In the last two decades, studies have suggested that low testosterone levels are associated with
increased prevalence of risk factors for cardiovascular disease (CVD), including dyslipidemia and
diabetes. This is a cross sectional study. The aim of our study was to determine the relationship between
serum testosterone levels and angiographic severity of coronary artery disease (CAD). Serum
testosterone levels were also correlated with ﬂow mediated dilation of brachial artery (BAFMD) – an
indicator of endothelial function. Consecutive male patients, aged 40–60 years, admitted for coronary
angiography (CAG) with symptoms suggestive of CAD, were included in the study. Out of the 92 patients
included in the study, 32 patients had normal coronaries and 60 had CAD on coronary angiography.
Severity of CAD was determined by Gensini coronary score. The group with CAD had signiﬁcantly lower
levels of total serum testosterone (363  147.1 vs 532.09  150.5 ng/dl, p < 0.001), free testosterone
(7.1215  3.012 vs 10.4419  2.75 ng/dl, p < 0.001) and bioavailable testosterone (166.17  64.810 vs
247.94  62.504 ng/dl, p < 0.001) when compared to controls. Adjusting for the traditional risk factors for
CAD, a multiple linear regression analysis showed that low testosterone was an independent predictor of
severity of CAD (b = 0.007, p < 0.001). This study also showed that levels of total, free and bioavailable
testosterone correlated positively with BAFMD %.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cardiovascular diseases (CVD) are the leading cause of death
world wide and coronary artery disease (CAD) is the most
signiﬁcant contributor to this mortality.1 In addition, CVD
contributes to signiﬁcant morbidity and loss of disability adjusted
life years (DALYS).1 A wealth of information exists on the
association of traditional coronary risk factors with CAD.2–4 In
the last two decades, there has been an emergence of several non-
traditional risk factors which are associated with an inﬂammatory
and pro-coagulant states in patients with CAD.5 Studies in
hypogonadal males have shown an increased prevalence of theAbbreviations: FBS, fasting blood sugar; BMI, body mass index; BAFMD, brachial
artery ﬂow mediated dilatation; CAD, coronary artery disease; CAG, coronary
angiography; CVD, cardiovascular disease; CLIA, chemiluminescence; DALYS,
disability adjusted life years; HDL-C, high density lipoprotein cholesterol; IHD,
ischemic heart disease; LDL-C, low density lipoprotein cholesterol; PP, post-
prandial blood sugar; SHBG, sex hormone binding globulin; TG, triglyceride.
* Corresponding author at: Department of Cardiology, Christian Medical College
Hospital, Vellore 632004, India.
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creativecommons.org/licenses/by-nc-nd/4.0/).traditional coronary risk factors and CAD.6,7 Furthermore, andro-
gen replacement therapy has been shown to improve risk factor
proﬁle and symptoms of ischemia in hypogonadal males.8–10
Phillips et al.11 was the ﬁrst to report an inverse correlation
between angiographically proven CAD and testosterone levels
after adjustment for adiposity and age. Yeap et al.12 found that the
highest quartile for serum testosterone was associated with the
lowest mortality and the lowest 2 quartiles with higher mortality.
Additional studies too indicated an association between incidence
of CAD and testosterone concentrations.13–20 However, a recent
study showed no signiﬁcant correlation between serum testoster-
one levels and CAD severity.21 Nevertheless, testosterone levels
were lower in CAD patients as compared to those with normal
coronaries in this study. Above evidences suggest involvement of
testosterone in the pathogenesis of CAD; that of a potentially
protective role against development and progression of CAD.
Additionally, patients with low testosterone levels have been
found to have impaired endothelial function which may contribute
to the increased cardiovascular risk in them.22,23
In this cross sectional observational study, we aimed to
determine the relationship between serum testosterone levels
and angiographic severity of CAD in middle-aged Indian men.marker of coronary artery disease severity in middle aged males,
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serum testosterone levels and ﬂow mediated dilation of brachial
artery (BAFMD) – an indicator of endothelial function.
2. Materials and methods
This cross sectional study was performed in consecutive male
patients aged 40–60 years admitted for coronary angiogram, in
the department of Cardiology from 1/10/2013 to 30/9/2014. The
exclusion criteria were: previous revascularization procedure,
patients not giving consent, history of hypogonadism, patients of
prostate cancer taking anti-androgens, liver/renal dysfunction,
recent myocardial infarction, and recent or current infection.
Written informed consent was obtained from all patients before
sample collection and angiography. The study was approved by the
Institutional Review Board and the Ethics committee of Christian
Medical College Vellore. The study conformed to Good Clinical
Practice and the ethical principles guiding human research. Out of
all the patients who had angiography, 92 middle-aged males were
recruited, and were divided into two groups according to coronary
angiography (CAG) ﬁndings – 32 patients had normal coronaries
and 60 had presence of CAD on CAG. Coronary artery disease was
deﬁned by the presence/absence of atherosclerotic plaques,
regardless of the degree of diameter stenosis.
2.1. Baseline data
Detailed socio-demographic and clinical characteristics were
recorded for each patient including age, gender, lifestyle,
hypertension, diabetes, dyslipidemia, smoking, history of ischemic
heart disease (IHD) and family history of IHD. Smoking habits were
categorized as current smoker-individuals who currently smoked
or quit <3 months prior to CAG or non-smoker. Weight and height
were recorded after admission and body mass index (BMI) was
calculated as weight in kilograms divided by the square of height in
meters.
2.2. Sample collection and laboratory measurements
Blood samples were drawn in the morning, prior to the
coronary angiogram and after 8 h overnight fasting. The blood
glucose, serum lipid and creatinine levels were measured by
enzymatic methods on an automated analyser. Serum fasting
testosterone was measured by automated chemiluminescence
method, using Siemens Immulite 2000 Xpi machine (Siemens,
Munich, Germany) (normal levels for men aged 20–49 years: 270–
1030 ng/dl; >50 years: 212–755 ng/dl).
Serum sex hormone binding globulin (SHBG) was measured by
automated electro-chemiluminescence method, using Roche E170
Modular machine (Roche Diagnostics, Basel, Switzerland). Free and
bio-available testosterone levels were calculated from serum total
testosterone and SHBG using an online calculator.
2.3. Coronary angiography and Gensini coronary score
Severity and extent of CAD was determined by the Gensini
scoring system, an index that assesses severity based on the
number of vessels affected, localization of segment, and grading of
the stenosis.24 Gensini score has been shown to correlate with CAD
progression and overall as well as CVS mortality.25 The Gensini
score was calculated as follows: grading of narrowing of a coronary
artery determined by eyeballing as; 1 for 25% narrowing, 2 for
26–50% narrowing, 4 for 51–75% narrowing, 8 for 76–90%
narrowing, 16 for 91–99% narrowing, and 32 for total occlusion.
Next, this primary score is multiplied by a factor that takes into
account the importance of position of lesion in the coronaryPlease cite this article in press as: Gururani K, et al. Testosterone as a
Indian Heart J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.07.002arterial tree: ﬁve for the left main, 2.5 for proximal left anterior
descending or proximal left circumﬂex artery and 1.5 for mid-
region, 1 for the distal left anterior descending and 1 for mid-distal
region of the left circumﬂex or right coronary artery. Gensini score
was expressed as the sum of the scores for all three coronary
arteries to evaluate the entire extent of coronary artery disease.
Angiographic scoring was done by cardiologist who was unaware
of biochemistry values in order to avoid bias.
2.4. BAFMD assessment
The examination was carried out in a quiet air conditioned
room with patient in a supine position. A longitudinal section of
the brachial artery was analyzed with B mode ultrasound using a
Philips iE 33 Ultrasound machine and a linear array transducer
(Philips Medical Systems, Andover, MA, USA). After baseline
measurement, a cuff which was placed above the transducer
position, was inﬂated to supra systolic pressure to produce
ischemia in the forearm. The cuff was deﬂated after 5 min. BAFMD
was calculated as percentage increase in diameter from baseline to
maximum value which is obtained after cuff deﬂation, BAFMD
% = [(diameter, maximum-diameter, baseline)/diameter, base-
line]  100.
2.4.1. Data collection and statistical analysis
Continuous variables were expressed as mean value  stan-
standard deviation (SD). Categorical variables were presented as
absolute values (percentages). The study population was divided
into two groups according to angiographic ﬁnding: CAD subjects and
normal coronaries (controls). Baseline characteristics of the two
groups were noted and compared. Comparisons between the two
groups pertaining to categorical data were done by chi-squared test
or Fisher’s exact test, wherever appropriate. Comparisons pertaining
to quantitative data were done by t-tests. Correlations between
serum total, free and bio-available testosterone levels and Gensini
scores as well as BAFMD were assessed using Pearson’s correlation
test. Similarly, correlations between serum testosterone and
traditional risk factors for CAD were also assessed. A multivariate
regression analysis was done to assess whether serum testosterone
was independently associated with CAD after adjusting for age, BMI,
smoking history, hypertension, diabetes mellitus, dyslipidemia and
history and treatment of IHD. A two sided p values <0.05 were
considered signiﬁcant for all tests. All statistical analyses were
performed using SPSS 19.0 (IBM SPSS, Chicago, IL, USA).
3. Results
3.1. Baseline, clinical and biochemical characteristics
Baseline and clinical characteristics of the two study groups are
displayed in Table 1. Age, diabetes mellitus and history of ischemic
heart disease (IHD) differed among the two study groups
signiﬁcantly (all p < 0.05). As expected, CAD group had greater
age, higher incidence of diabetes mellitus and history of IHD than
controls. However, there were no statistically signiﬁcant difference
between the two groups for hypertension, obesity, smoking and
dyslipidemia (p > 0.05). The values of fasting (FBS) and post-
prandial sugars (PPBS) were signiﬁcantly higher in patients with
CAD when compared to those with normal coronaries (Table 2).
Serum lipid levels did not differ between the two groups
signiﬁcantly.
The mean values of serum total, free and bioavailable
testosterone were signiﬁcantly lower inpatients with CAD when
compared to controls (p < 0.001 for all).
CAD group also had signiﬁcantly lower BAFMD values in
comparison to subjects with normal coronaries (p < 0.001). marker of coronary artery disease severity in middle aged males,
Table 2
Results of Lab values in patients with CAD and normal coronaries.
Variables CAD (N = 60)
(mean  S.D.)
Normal coronaries
(N = 32)
(mean  S.D.)
p value
Creatinine (mg/dl) 0.9742  0.169 0.9928  0.1888 0.63
Total cholesterol (mg/dl) 157.12  38.483 155.22  40.401 0.825
Triglyceride (mg/dl) 173.48  95.162 140.78  63.653 0.086
HDL (mg/dl) 37.15  7.655 37.41  7.987 0.880
LDL (mg/dl) 100.4  36.851 97.97  33.299 0.756
Fasting blood sugar (mg/dl) 136.42  50.316 103.41  15.206 <0.001
Post-prandial blood sugar
(mg/dl)
194.33  85.291 130.88  30.650 <0.001
Total testosterone (ng/dl) 363  147.174 532.09  150.553 <0.001
Sex hormone binding
globulin (nmol/l)
35.5467  11.442 37.3509  10.502 0.450
Free testosterone (ng/dl) 7.1215  3.012 10.4419  2.75 <0.001
Bioavailable testosterone
(ng/dl)
166.17  64.810 247.94  62.504 <0.001
Brachial artery ﬂow
mediated dilation (%)
11.660  4.4 18.143  3.301 <0.001
p value is statistically signiﬁcant as mentioned under Section 2.4.1.
Table 1
Baseline and clinical characteristics of study population.
Variables CAD (N = 60) Normal coronaries
(N = 32)
p value
Age (mean  standard deviation) 54  6 51  7 0.014
Obesity 32 (53.3%) 16 (50%) 0.760
Diabetes 36 (60%) 7 (21.9%) <0.001
Hypertension 38 (63.3%) 18 (56.2%) 0.507
Smoking 25 (41.7%) 10 (31.2%) 0.327
Dyslipidemia 22 (36.7%) 11 (34.4%) 0.827
History of ischemic heart
disease
11 (18.3%) 1 (3.125%) 0.007
p value is statistically signiﬁcant as mentioned under Section 2.4.1.
Fig. 1. Scatter diagram showing a negative correlation between serum 
K. Gururani et al. / Indian Heart Journal xxx (2016) xxx–xxx 3
G Model
IHJ-1006; No. of Pages 5
Please cite this article in press as: Gururani K, et al. Testosterone as a 
Indian Heart J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.07.0023.1.1. Correlations between serum total testosterone levels, CAD risk
factors, Gensini score and BAFMD
There was a signiﬁcant negative correlation between serum
total testosterone levels and Gensini scores (r = 0.481, p < 0.001)
(Fig. 1 – scatter plot). The total testosterone concentrations also
correlated negatively with the traditional risk factors for CAD like
age, hypertension, BMI and serum cholesterol levels, but this
correlation was statistically signiﬁcant only for serum triglycerides
(r = 0.224, p = 0.032) and diabetes – FBS (r = 0.303, p = 0.003)
and PPBS (r = 0.284, p = 0.006) (Table 3). There was a signiﬁcant
positive correlation between BAFMD and serum total testosterone
levels (r = 0.572, p < 0.001).
Similarly, serum free testosterone levels also showed statisti-
cally signiﬁcant negative correlation with Gensini score (r = 0.480,
p < 0.001) and statistically signiﬁcant positive correlation with
BAFMD (r = +0.525, p < 0.001). Bioavailable testosterone levels
also correlated negatively with Gensini score (r = 0.524, p < 0.001)
and positively with BAFMD (r = 0.547, p < 0.001).
3.1.2. Predictors of CAD severity
The inﬂuence of serum testosterone levels on CAD was assessed
after adjustment for age, BMI, smoking history, hypertension,
diabetes mellitus, dyslipidemia and history and treatment of IHD
in a multivariate regression model. Age, smoking status and serum
testosterone levels were found to be independent predictors for
higher Gensini score or severity of CAD (Table 4).
4. Discussion
The present study, a cross sectional observational study,
demonstrated a statistically signiﬁcant negative correlation
between severity of CAD and serum total, free and bioavailable
testosterone levels in middle aged Indian men. This study also
showed that levels of total, free and bioavailable testosteronetotal testosterone levels and Gensini scores (r = 0.481, p < 0.001).
marker of coronary artery disease severity in middle aged males,
Table 3
Association of serum total testosterone with CAD risk factors, Gensini score and
brachial artery ﬂow mediated dilation.
Variables Correlation coefﬁcient p value
Age 0.088 0.405
BMI (kg/m2) 0.077 0.464
Fasting blood sugar (mg/dl) 0.303 0.003
Post-prandial blood sugar (mg/dl) 0.284 0.006
Systolic B.P. (mmHg) 0.042 0.691
Disatolic B.P. (mmHg) 0.143 0.174
Total cholesterol (TC) (mg/dl) 0.181 0.083
Triglyceride (TG) (mg/dl) 0.224 0.032
HDL (mg/dl) 0.074 0.481
LDL (mg/dl) 0.140 0.183
Brachial artery ﬂow mediated dilation (%) 0.572 0.001
Gensini score 0.481 0.001
p value is statistically signiﬁcant as mentioned under Section 2.4.1.
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function. This association remained signiﬁcant even after adjust-
ment for well-established traditional cardiovascular risk factors.
To the best of our knowledge, no study has been done till date to
assess the relationship of serum testosterone levels with CAD
severity and impairment of endothelial function in middle aged
Indian men.
The ﬁndings are similar to previous studies done by Hu et al.19
and Li et al.26 that showed an inverse association between serum
testosterone and Gensini score. However, some prior studies have
failed to show a deﬁnite association between serum testosterone
levels and CAD.20,27,28 Yet another study suggested a nonlinear
association of testosterone levels with CAD: lower levels have a
preventive effect on CAD, whereas higher values increase the risk
of CAD.29 Some studies that showed a signiﬁcant correlation
between androgens and CAD severity included patients with acute
coronary syndrome.16 Inclusion of these patients could confound
the results since hormone levels might be affected by acute
myocardial infarction. Hence, our study included only patients
with stable CAD. The heterogeneous ﬁndings concerning associa-
tion of testosterone and CAD likely reﬂect complexity of
pathogenesis of CAD. Given this backdrop of contradictory
evidences, ﬁndings of our study lend a stronger support toward
a relevant impact of testosterone on CAD and endothelial function
in males.
The levels of total, free and bioavailable testosterone were
signiﬁcantly lower in the CAD group as compared to that in
patients with normal coronaries, on univariate analysis. Some
baseline characteristics such as age, diabetes mellitus and BMI may
affect testosterone levels.30,31 In our study groups, BMI was similar.
But there were signiﬁcant differences in the mean age and
prevalence of diabetes, and therefore we analyzed the association
between serum testosterone and CAD in a multivariate regression
model, after correcting for traditional risk factors. Results showed
low serum testosterone to be an independent predictor for Gensini
score or severity of CAD. The current study ﬁndings thus provideTable 4
Multiple linear regression analysis with Gensini score as the dependent variable.
Variables b coefﬁcient Lower
limit
Upper
limit
p value
Age (years) 0.099 1.011 1.205 0.028
BMI (kg/m2) 0.097 0.777 1.059 0.218
Diabetes 0.943 0.785 8.387 0.119
Dyslipidemia 0.040 0.323 3.349 0.947
Hypertension 0.005 0.299 3.310 0.993
Smoker 1.166 0.951 10.824 0.050
Serum total testosterone (ng/dl) 0.007 0.989 0.997 <0.001
p value is statistically signiﬁcant as mentioned under Section 2.4.1.
Please cite this article in press as: Gururani K, et al. Testosterone as a
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with traditional coronary risk factors. The study excluded patients
with acute and chronic illnesses, and hence it is unlikely that these
factors contributed to lower levels of testosterone in our study.
In the present study, the absolute value of BAFMD was
signiﬁcantly higher in the controls than in cases, which suggests
that endothelial function was better inpatients with higher
testosterone levels. Since all the traditional risk factors for CAD
affect endothelial function adversely, the relationship between
testosterone levels and BAFMD was also assessed after adjusting
for all coronary risk factors using a regression model. The
testosterone levels were associated with BAFMD %, independent
of all confounding risk factors.
In our study total, free and bioavailable testosterone correlated
negatively with age, but the correlation was signiﬁcant only for
bioavailable testosterone. A signiﬁcant negative correlation was
observed between total, free and bioavailable testosterone levels
and blood sugars. Studies done by Stellato et al.,32 Selvin et al.,33
Haring et al.,34 and Oh et al.35 have shown a negative correlation
between testosterone and diabetes or components of the
metabolic syndrome. Our study also showed negative correlation
between total, free and bioavailable testosterone levels with BMI,
total cholesterol and low density lipoprotein (LDL) cholesterol and
triglyceride levels (statistically insigniﬁcant). Earlier studies have
found that testosterone levels correlate inversely with obesity and
cholesterol levels.9,36 Testosterone replacement therapy has been
shown to improve BMI in clinical studies.37,38 The testosterone
levels correlated positively with HDL levels in our study, but it was
also not statistically signiﬁcant.
Exact mechanisms linking low testosterone and CAD have not
been fully elucidated, and are likely to involve complex inter-
connected processes including accelerated atherosclerosis, abnor-
mal activation of inﬂammatory response, impaired vasomotion
and endothelial dysfunction. Additional investigations are re-
quired to further clarify the relationship between low testosterone
levels and CAD.
5. Limitations
The study had a few limitations. Firstly, cross-sectional design
of this study made it impossible to determine whether CAD
preceded or followed the decline in serum testosterone level.
Hence, a causal relationship between CAD and testosterone could
not be deduced. Since measurement of testosterone was single
sample, ﬂuctuations in serum testosterone values over time could
not be assessed. As study was performed in a single center and of a
relatively smaller sample size, a selection bias cannot be ruled out.
There were signiﬁcant differences pertaining to age, diabetes and
history of IHD between the two groups which could have affected
our ﬁnal results. However, these differences do exist between CAD
subjects and the general population and furthermore, a multivari-
ate analysis performed after adjusting for these potential
confounders showed independent association between CAD and
testosterone levels. Even though testosterone levels were corre-
lated with CAD severity, our patients were not followed up to
monitor the ﬁnal outcomes in terms of mortality. Longitudinal
studies might provide valuable additional information regarding
role of testosterone in the pathogenesis and outcomes of CAD.
6. Conclusion
Our study suggests low testosterone levels is an independent
risk predictor for CAD and endothelial dysfunction. A randomized
controlled trial of testosterone replacement in hypogonadal males
and evaluation of its effects on endothelial function, risk factors for
cardiovascular disease, CAD progression and outcomes, is needed marker of coronary artery disease severity in middle aged males,
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present study is the ﬁrst study done on an Indian population and it
corroborates with studies done in other population groups. The
exact mechanism underlying our results and its clinical relevance
require further elucidation by pathogenetic and long-term clinical
studies.
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